Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age (SGA OPTIMIS)

This study has been completed.
Sponsor:
Collaborator:
Merck Serono S.A.S., an affiliate of Merck KGaA, Darmstadt, Germany
Information provided by (Responsible Party):
Merck KGaA
ClinicalTrials.gov Identifier:
NCT00249821
First received: November 4, 2005
Last updated: December 2, 2013
Last verified: December 2013
  Purpose

Multicentric, open-label, randomized, pilot comparative study in parallel groups comparing 1 group of subjects receiving 0.057 milligram/kilogram/day (mg/kg/day) or 0.40 mg/kg/week of Saizen® during 1 year to 1 group receiving 0.035 mg/kg/day (0.24 mg/kg/week) of Saizen® during 1 year after an initial 3-year treatment of recombinant human growth hormone (r-hGH) therapy with 0.057 mg/kg/day in both groups.


Condition Intervention Phase
Small for Gestational Age (SGA)
Drug: Saizen®
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Optimization of the Dosage Regimen With Growth Hormone Therapy in Children Born Small for Gestational Age. An Open Label, Randomized, Pilot Study, Comparing in Children Treated for 3 Years, the Efficacy of a Saizen® Treatment at the Same Dose Versus a Lower Maintenance Dose Prolonged During 1 Additional Year.

Resource links provided by NLM:


Further study details as provided by Merck KGaA:

Primary Outcome Measures:
  • Height Velocity [ Time Frame: Month 12 ] [ Designated as safety issue: No ]

    Height Velocity (HV) is the change in height since the previous year´s measurement and more precisely:

    HV = {(h-hp)/(d-dp)} * 365.25 [centimeter (cm)/year] where h is current height in cm, hp is previous height in cm, closest to 1 year previous, d is the current date and dp is the date of measurement of previous height, closest to 1 year previous. Additionally, d and dp have to be within 0.6 years and 1.5 years.

    HV is the mean height velocity over the interval between d and dp but is displayed as HV at d.



Secondary Outcome Measures:
  • Change From Baseline in Height-Standard Deviation Score (H-SDS) at Month 6 and Month 12 [ Time Frame: Baseline (randomization), Month 6 and Month 12 ] [ Designated as safety issue: No ]
    Height-Standard Deviation Score (H-SDS) was calculated as height minus mean (age-and sex-matched reference) divided by standard deviation (SD) [age and sex-matched reference]. Greater H-SDS indicates greater height.

  • Height Velocity-Standard Deviation Score (HV-SDS) [ Time Frame: Month 6 and Month 12 ] [ Designated as safety issue: No ]
    Height Velocity-Standard Deviation Score (HV-SDS) was calculated as height velocity minus reference mean height velocity divided by SD of the reference mean height velocity. Greater HV-SDS indicates greater height velocity.

  • Change From Baseline in Height at Month 6 [ Time Frame: Baseline (randomization) and Month 6 ] [ Designated as safety issue: No ]
  • Change From Baseline in Bone Age at Month 12 [ Time Frame: Baseline (randomization) and Month 12 ] [ Designated as safety issue: No ]
    Bone age was assessed by a left wrist X-Ray and evaluated by the investigator according to the Greulich and Pyle method.

  • Insulin Like Growth Factor-1 (IGF-1) Levels [ Time Frame: Baseline (randomization), Month 6 and Month 12 ] [ Designated as safety issue: No ]
  • Insulin Like Growth Factor Binding Protein-3 (IGFBP-3) Levels [ Time Frame: Baseline (randomization), Month 6 and Month 12 ] [ Designated as safety issue: No ]
  • Number of Participants With Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Baseline (randomization) until Month 12 ] [ Designated as safety issue: Yes ]
    Adverse Events (AEs): Any untoward medical occurrence in the form of signs, clinically significant abnormalities in laboratory findings, diseases, symptoms, or worsening of complications. TEAEs: AEs that occur during treatment with the Investigational Medicinal Product (IMP).


Enrollment: 22
Study Start Date: February 2005
Study Completion Date: September 2007
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Saizen® 0.057 mg/kg/day
Subjects who met all inclusion/exclusion criteria were randomly assigned to 0.057 mg/kg/day in this multi-center study. Subjects were stratified at randomization according to the Height-Standard Deviation Score (H-SDS) at this time (less than [<] -2 SDS or greater than [>] -2 SDS)
Drug: Saizen®
Saizen® [somatropin (recombinant deoxyribonucleic acid [rDNA] origin) for injection], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
Other Name: somatropin
Experimental: Saizen® 0.035 mg/kg/day
Subjects who met all inclusion/exclusion criteria were randomly assigned to 0.035 mg/kg/day in this multi-center study. Subjects were stratified at randomization according to the H-SDS at this time (< -2 SDS or > -2 SDS)
Drug: Saizen®
Saizen® [somatropin (rDNA origin) for injection], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
Other Name: somatropin

  Eligibility

Ages Eligible for Study:   6 Years to 11 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

To be eligible for inclusion / randomization into this study, the subjects must fulfill all of the following criteria (if there is no inclusion phase, the inclusion criteria will be considered as inclusion criteria for randomization):

  • Written consent form signed by the parents / legal guardian, and child if possible
  • Subject born SGA and receiving a r-hGH therapy for this pathology
  • Recombinant human growth hormone (r-hGH) started at the maximal chronological age of 7 years for girls and 8 years for boys
  • Treatment with r-hGH started for at least 30 months and less than 36 months at 0.057 mg/kg/day
  • Height gain during the first 2 years of GH treatment > 1 SD compared with the initial value

Exclusion Criteria:

To be eligible for inclusion in this study the subjects must not meet any of the following criteria:

  • Known hypersensitivity to Somatropin or any of the excipients
  • Active neoplasia (either newly diagnosed or recurrent)
  • Intracranial hypertension
  • Known diabetes mellitus
  • Proliferative or preproliferative diabetic retinopathy
  • Evidence of any progression or recurrence of an underlying intra-cranial space occupying lesion
  • Obesity defined as degree 1 on the corpulence curves
  • Precocious puberty
  • Pubertal status: Tanner breast development stage > 2 for girls, and testicular volume > 4 milliliter (mL) or testicular length > 3 centimeter (cm) and/or testosterone value >1 nanomole/liter [nmol/L] (0.29 gram/mL [g/mL]) for boys For girls > 9 years and Tanner breast development stage 1: uterine size > 35 millimeter (mm)
  • Severe chronic concomitant illness such as chronic renal failure, cystic fibrosis
  • Concomitant corticoid treatment or levothyroxine treatment other than substitutive treatment, topical or inhaled treatment
  • Participation to any clinical study within the 30 days preceding study entry
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00249821

Sponsors and Collaborators
Merck KGaA
Merck Serono S.A.S., an affiliate of Merck KGaA, Darmstadt, Germany
Investigators
Study Director: Laurence Fresneau, M.D. Merck Serono S.A.S, France
  More Information

Additional Information:
Publications:
Responsible Party: Merck KGaA
ClinicalTrials.gov Identifier: NCT00249821     History of Changes
Other Study ID Numbers: IMP 25735
Study First Received: November 4, 2005
Results First Received: June 28, 2012
Last Updated: December 2, 2013
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
France: French Data Protection Authority
France: Institutional Ethical Committee

Additional relevant MeSH terms:
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 01, 2014